-$0.39 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
Equities analysts predict that Proteon Therapeutics, Inc. (NASDAQ:PRTO) will announce earnings per share (EPS) of ($0.39) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Proteon Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.52) and the highest estimate coming in at ($0.34). Proteon Therapeutics reported earnings per share of ($0.43) in the same quarter last year, which would indicate a positive year over year growth rate of 9.3%. The business is expected to report its next earnings report on Monday, November 6th.
According to Zacks, analysts expect that Proteon Therapeutics will report full-year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.72) to ($1.42). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.64) per share, with EPS estimates ranging from ($1.81) to ($1.35). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Proteon Therapeutics.
Proteon Therapeutics (NASDAQ:PRTO) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.11.
Several equities research analysts recently weighed in on the stock. HC Wainwright set a $3.00 price target on shares of Proteon Therapeutics and gave the company a “hold” rating in a research report on Saturday, May 13th. Oppenheimer Holdings, Inc. reissued a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Cowen and Company reissued a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. Zacks Investment Research downgraded shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Maxim Group set a $6.00 price objective on shares of Proteon Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.
ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/0-39-earnings-per-share-expected-for-proteon-therapeutics-inc-prto-this-quarter/1516235.html.
Proteon Therapeutics (PRTO) traded up 3.85% during trading on Tuesday, hitting $1.35. The stock had a trading volume of 15,593 shares. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $11.45. The stock’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.51. The company’s market capitalization is $23.79 million.
A hedge fund recently bought a new stake in Proteon Therapeutics stock. RA Capital Management LLC purchased a new position in Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up about 0.2% of RA Capital Management LLC’s holdings, making the stock its 22nd largest position. RA Capital Management LLC owned approximately 7.59% of Proteon Therapeutics at the end of the most recent quarter. 41.08% of the stock is owned by institutional investors.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.